{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:43:26Z","timestamp":1790343806579,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combination of pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed\/refractory MM. Therefore, we studied adding elotuzumab to PVd (elo-PVd) in relapsed\/refractory MM in a multicenter phase 2 trial. The primary objective was to determine the overall response rate (ORR). Patients with relapsed\/refractory disease and \u22651 prior line of treatment (including lenalidomide and a proteasome inhibitor) were eligible. For each 28-day cycle, elotuzumab was weekly for the first 2 cycles and then every other week; pomalidomide on days 1 to 21; bortezomib on days 1, 8, and 15; and dexamethasone weekly. The trial enrolled 48 patients with a median 3 prior lines (range, 1-9). Prior therapies included pomalidomide (33%), daratumumab (25%), and isatuximab (4%). The ORR was 56.3%, and the median progression-free survival (PFS) was 10\u00a0months. In patients with 1 prior line of therapy, ORR was 73.7%; median PFS was 23.4\u00a0months. Common grade \u22653 adverse events were neutropenia (33%); infections, any (33%); lung infection (27%); hypophosphatemia (19%); and thrombocytopenia (15%). Elo-PVd is, to our knowledge, one of the first trials of a quadruplet regimen in relapsed\/refractory MM incorporating a monoclonal antibody to show efficacy across diverse prior treatments, including triple-class exposed patients with prior anti-CD38 monoclonal antibody. This trial was registered at ClinicalTrials.gov as #NCT02718833.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014717","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T22:28:39Z","timestamp":1733264919000},"page":"1163-1170","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"first","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-2052","authenticated-orcid":false,"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3260","authenticated-orcid":false,"given":"Erica L.","family":"Campagnaro","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brea C.","family":"Lipe","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb S.","family":"Friedman","sequence":"additional","affiliation":[{"name":"6Newton-Wellesley Hospital, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Cole","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9267","authenticated-orcid":false,"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Schlossman","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C.","family":"Harrington","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill N.","family":"Burke","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn T.","family":"Gammon","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J.","family":"Lively","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra A.","family":"Reimonn","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle X.","family":"Andrade","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":false,"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens G.","family":"Lohr","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"7","key":"2025032513473917700_bib1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2025032513473917700_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2025032513473917700_bib3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2025032513473917700_bib4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2025032513473917700_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2025032513473917700_bib6","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2025032513473917700_bib7","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2025032513473917700_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025032513473917700_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025032513473917700_bib10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2015.125864","article-title":"Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"100","author":"San Miguel","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"2025032513473917700_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"2025032513473917700_bib12","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2025032513473917700_bib13","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","article-title":"Cell-free DNA for the detection of emerging treatment failure in relapsed\/ refractory multiple myeloma","volume":"36","author":"Waldschmidt","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2025032513473917700_bib14","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2025032513473917700_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clml.2023.03.016","article-title":"A\u00a0clinical and correlative study of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (elo-KRd) for lenalidomide refractory multiple myeloma in first relapse","volume":"23","author":"Bhutani","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"2025032513473917700_bib16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032513473917700_bib17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10214","key":"2025032513473917700_bib18","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2025032513473917700_bib19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10292","key":"2025032513473917700_bib20","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"10245","key":"2025032513473917700_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"2025032513473917700_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2025032513473917700_bib23","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032513473917700_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK cell phenotype in the disease course of multiple myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers"},{"issue":"23","key":"2025032513473917700_bib25","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2025032513473917700_bib26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10428194.2019.1688324","article-title":"Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma","volume":"61","author":"Hoylman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025032513473917700_bib27","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1007\/s00277-024-05705-z","article-title":"Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study","volume":"103","author":"Nakamura","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"2025032513473917700_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025032513473917700_bib29","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2025032513473917700_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-023-00785-y","article-title":"Defining drug\/drug class refractoriness vs lines of therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Goel","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025032513473917700_bib31","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.18657","article-title":"Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma","volume":"200","author":"Costa","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2025032513473917700_bib32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032513473917700_bib33","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025032513473917700_bib34","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S2352-3026(23)00366-6","article-title":"Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial","volume":"11","author":"Mai","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025032513473917700_bib35","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 16","key":"2025032513473917700_bib36","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study [abstract]","volume":"41","author":"Knop","year":"2023","journal-title":"J\u00a0Clinical Oncol"},{"issue":"10","key":"2025032513473917700_bib37","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025032513473917700_bib38","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"2025032513473917700_bib39","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2025032513473917700_bib40","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S2152-2650(23)01667-1","article-title":"P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (cilta-cel) for relapsed\/refractory multiple myeloma (RRMM): real world experience","volume":"23","author":"Sidana","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2025032513473917700_bib41","article-title":"Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial [abstract]","volume":"142","author":"Richardson","year":"2023","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1163\/2357732\/blooda_adv-2024-014717-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1163\/2357732\/blooda_adv-2024-014717-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:25:30Z","timestamp":1742948730000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1163\/534297\/Elotuzumab-in-combination-with-pomalidomide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014717","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}